The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies

SpringerPlus

Table 3 Adjusted mean FEV ₁ AUC _0–12 , FEV ₁ AUC _12–24 , and FEV ₁ AUC _0–24 responses (L); comparisons across active treatment arms after 6 weeks (pooled analysis)

	Treatment difference
	FEV₁AUC_0–12	P value	FEV₁AUC_12–24	P value	FEV₁AUC_0–24	P value
	Mean (SE)		Mean (SE)		Mean (SE)
Olodaterol 10 μg QD vs 5 μg QD	0.001 (0.012)	.9527	0.010 (0.013)	.4423	0.005 (0.012)	.6474
Olodaterol 10 μg QD vs formoterol 12 μg BID	0.011 (0.012)	.3588	−0.040 (0.013)	.0024	−0.014 (0.012)	.2268
Olodaterol 5 μg QD vs formoterol 12 μg BID	0.011 (0.012)	.3876	−0.050 (0.013)	.0001	−0.020 (0.012)	.0944

AUC_0–12 = area under the curve from 0 to 12 h; AUC_0–24 = area under the curve from 0 to 24 h; AUC_12–24 = area under the curve from 12 to 24 h; BID = twice daily; FEV₁ = forced expiratory volume in 1 sec; QD = once daily; SE = standard error.